January 30 – February 1, 2024 | Barcelona, Spain

With new clinical data and more ground-breaking advancements in the technology underpinning microbiome research, Europe’s leading microbiome organisations are paving the way for drug development!

As Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics, this is your prime opportunity to expand your microbiome-based drug development capabilities and business potential as the community aims to deliver clinical results and ensure therapeutic microbiome approval in Europe.

Joining this community of microbiome trailblazers is Beacon’s Microbiome Research Lead Analyst, Ada Lam. Providing ‘A 2023 Landscape Review and Future Outlooks of Microbiome Therapeutics‘, Ada’s session is set to not only document the progression of the preclinical and clinical landscapes within drug development but also compare this past year to the last 10 years and explore future outlooks for 2024. You can find out more information about Ada’s talk here or download the full agenda now.